Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
JPMorgan Take-Aways on Apellis Pharmaceuticals (APLS) Earnings
May 7, 2024 7:59 AM EDTJPMorgan analyst Anupam Rama reiterated an Overweight rating and $79.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "The quarter was highlighted by a 1Q24 beat for Syfovre, though we suspect the call will largely focus on near-term GA market dynamics post... More
